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E-mail address: monique.cadrin@uqtr.ca (M. CadriKeratin 8 and 18 are simple epithelial intermediate ﬁlament (IF) proteins, whose expression is dif-
ferentiation- and tissue-speciﬁc, and is maintained during tumorigenesis. Vimentin IF is often co-
expressed with keratins in cancer cells. Recently, IF have been proposed to be involved in signaling
pathways regulating cell growth, death and motility. The PI3K/Akt pathway plays a pivotal role in
these processes. Thus, we investigated the role of Akt (1 and 2) in regulating IF expression in differ-
ent epithelial cancer cell lines. Over-expression of Akt1 increases K8/18 proteins. Akt2 up-regulates
K18 and vimentin expression by an increased mRNA stability. To our knowledge, these results rep-
resent the ﬁrst indication that Akt isoforms regulate IF expression and support the hypothesis that
IFs are involved in PI3K/Akt pathway.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Intermediate ﬁlaments (IFs) constitute an extensive cytoskele-
tal network whose protein constituents are encoded by a large
family of genes that are expressed in a tissue- and differentiation
state-speciﬁc manner [1]. Keratins are the major IF proteins ex-
pressed in epithelial cells and are associated in obligate hetero-
polymers. The keratins 8 and 18 (K8/18) are typically co-
expressed and constitute the primary keratin pair in simple epithe-
lial cells. As part of the cytoskeleton, IFs are important in providing
mechanical stability and integrity of cells and tissues submitted to
mechanical and toxic stress. Moreover, recent studies have shown
that IFs are involved in signaling pathways which regulate epithe-
lial cell growth, resistance to apoptosis and motility [1].
K8/18 are expressed in most epithelial tumors (carcinomas) [2].
Moreover, vimentin, a mesenchymal-speciﬁc IFs protein, is often
co-expressed with keratins in late-stage epithelial cancer cells pre-
senting a dedifferentiated phenotype [3–5]. To understand the sig-
niﬁcance of IFs protein increase expression in cells, differentchemical Societies. Published by E
8, keratins 8 and 18; vim,
kt1, constitutively activated
, short hairpin RNA; GAPDH,
sphate buffered saline; CHX,
uébec à Trois-Rivières, 3351,
A 5H7. Fax: +1 819 376 5057.
n).researchers have addressed the question as to whether IFs expres-
sion affects tumor fate and behavior. It was reported that K18 over-
expression correlates with reduced invasive/metastatic potential
and tumorigenicity in a human breast cancer [6,7], whereas an en-
hanced migratory and invasive potential is observed in mouse
ﬁbroblasts [8]. The co-expression of keratins with vimentin is asso-
ciated with an increased metastatic potential [9] and down-regula-
tion of vimentin expression resulted in impaired invasion of colon
and breast cancer cell lines [10]. For this reason, it is generally
thought that the balance between keratins and vimentin expres-
sion in carcinoma cells would dictate cellular invasiveness and
metastatic potential. However, the molecular mechanisms regu-
lated by IFs as well as the regulation of their own expression pat-
tern in a context of normal and cancer cells remain poorly
understood.
Similar to IFs, phosphatidylinositol 3-kinase (PI3K)/Akt signal-
ing pathway plays a pivotal role in cell proliferation, survival and
migration. There are three isoforms of Akt. Ampliﬁcation of Akt1
and/or Akt2 isoforms is frequently found in human cancers [11]
and, increasing number of studies demonstrate isoforms-speciﬁc
functions for Akt kinases in carcinoma cells [12,13]. In breast can-
cer cells for example, it has been shown that over-expression of
Akt1 decreases cellular invasiveness [14] whereas over-expression
of Akt2, to the contrary, increases cellular invasiveness [15]. Akt3
has a minimal induction effect on these tumors [15]. Downstream
targets of Akt isoforms which mediate their role in cancer progres-
sion, however, are only partially elucidated.lsevier B.V. All rights reserved.
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increasing evidences that keratins could play a role in cell growth,
protein synthesis and cell cycle by regulating key signaling mole-
cules, like 14-3-3 proteins and proteins of the Akt-mTor pathway
[17,18]. Another function of Akt is to prevent apoptosis in both
intrinsic and extrinsic pathway [13,19]. IFs have been shown to
attenuate pro-apoptotic signals such as TNFa and Fas by scaffold-
ing and organizing death effector proteins [20–23]. Moreover,
Akt is an important modulator of cell motility and invasion [24]
and IFs are involved in cell migration and wound healing through
their interaction with adhesion proteins [25–27]. All these ﬁndings
suggest that IFs could be associated with Akt-regulated cellular
processes.
In the present study, we have investigated whether Akt1 and/or
Akt2 regulate the expression and organization of K8/18 and vimen-
tin in different epithelial cancer cell lines.
2. Materials and methods
2.1. Cell lines and reagents
Human endometrial carcinoma KLE cell line, human cervical
carcinoma HeLa cell line and human hepatocellular carcinoma
HepG2 cell line were purchased from ATCC. Cells were maintained
in growth medium supplemented with serum and 50 lg/mL genta-
mycin. Akt1, Akt2, pAkt (Ser-473) and pGSK3b (Ser-9) antibodies
were purchased from Cell Signaling Technology (Beverly, MA).
K8/18 antibodies were a generous gift from Dr. M. Bishr Omary
(University of Michigan, MI). Vimentin and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) antibodies were purchased
from Abcam (Cambridge, MA). LY294002 was from Cell Signaling
Technology. Cycloheximide and b-actin were from Sigma (St. Louis,
MO). Transforming growth factor b1 (TGF-b1) was purchased from
Calbiochem (San Diego, CA).
2.2. Transfection with short hairpin RNAs (shRNAs) and plasmids
Cells were transfected as described before [28] with Akt1,
Akt2 or control (scrambled) shRNAs (SABiosciences, Frederick,
MD), or constitutively active Akt1 vector (CA-Akt1), constitu-
tively active Akt2 vector (CA-Akt2) or empty pcDNA3.1 vector
[13].
2.3. Western blots and qRT-PCR
Total cellular proteins and mRNA were extracted as described
[28]. Quantitative real-time PCR was performed with LightCycler
480 (Roche, Laval, Canada) using K8 sense primer 50-agggctgacc-
gacgagat-30 and antisense 50-caccacagatgtgtccgaga-30; K18 sense
primer 50-tgatgacaccaatatcacacga-30 and antisense 50-
ggcttgtaggccttttacttcc-30; and vimentin sense primer 50-
aaagtgtggctgccaagaac-30 and antisense 50-agcctcagagaggtcagcaa-30
(Institute for Research in Immunology and Cancer, Montreal, Can-
ada). Samples were analyzed in triplicates from three independent
experiments. Relative quantiﬁcation of expression was calculated
by the comparative 2DDCT method [29] with GAPDH and TBP as
reference genes.
2.4. Immunoﬂuorescence
Cells were grown on glass coverslips, ﬁxed with 4% paraformal-
dehyde for 10 min, washed twice in phosphate buffered saline
(PBS) and permeabilized for 10 min in citrate solution (0.1% so-
dium citrate, 0.1% Triton X-100 in PBS) at room temperature. Triple
immunoﬂuorescence staining was performed as described before
[28].2.5. Statistical analyses
The data were subjected to one-way ANOVA analysis of vari-
ance (PRISM software version 3.03; GraphPad, San Diego, CA). Dif-
ferences between experimental groups were determined by the
Tukey’s test. Statistical signiﬁcance was accepted when P < 0.05.3. Results
3.1. Akt1 and Akt2 isoforms differentially-regulates IF proteins levels in
epithelial carcinoma cells
To determine whether Akt isoforms can affect IFs expression
in epithelial carcinoma cells, we used three epithelial carcinoma
cell lines whose various differentiation state and p-Akt levels
constitute an interesting experimental model: two p-Akt-nega-
tive cell lines, HepG2 and HeLa cells, obtained, respectively,
from well and moderately-differentiated epithelial carcinoma,
and one p-Akt-positive and poorly-differentiated cell line, KLE
cells.
We have investigated the role of Akt1 and Akt2 isoforms in
regulating the expression of IFs proteins in p-Akt-negative HeLa
and HepG2 cells. Cells were transfected with constitutively
active Akt (CA-Akt) constructs inducing the expression of myri-
stoylated Akt proteins, which are constitutively phosphorylated/
activated in the cells [13]. Increased phosphorylation of Akt pro-
teins as well as one of their substrate GSK3b (Fig. 1A and B) con-
ﬁrms that CA-Akt proteins are active in our experimental
conditions.
Our results show that over-expression of CA-Akt1 isoform in p-
Akt-negative HeLa and HepG2 cells increases K8 and 18 protein
levels in the two cell lines. Vimentin, which is only detectable in
HeLa cells, is not signiﬁcantly affected (Fig. 1A). On the other hand,
expression of CA-Akt2 isoform up-regulates K18 protein level in
the two cell lines, while K8 is not affected. Interestingly, unlike
CA-Akt1, over-expression of CA-Akt2 isoform signiﬁcantly up-reg-
ulates vimentin protein levels (Fig. 1B). These results suggest that
activation of Akt1 and Akt2 regulates IFs protein expression and
that the regulation is Akt isoform-speciﬁc.
We also examined whether increase in K8/18 was regulated at
transcriptional or posttranscriptional level. We found that trans-
fection of HepG2 and HeLa cells with CA-Akt1 and CA-Akt2 had
no effect on K8, K18 or vimentin mRNAs (Fig. 1C). Thus, the regu-
lation of IFs protein levels by Akt1 and Akt2 activation occurs at the
posttranscriptional level.
In the opposite manner, we have analyzed the role of Akt1 and
Akt2 isoforms in regulating the expression of IFs in p-Akt-positive
KLE cells using shRNA. Knockdown of Akt1 decreases K8 protein le-
vel, whereas K18 and vimentin expression were not affected
(Fig. 1D). This could be explained by the presence of active Akt2
isoform in KLE cells, which could maintain K18 and vimentin at a
high level. For instance, Akt2 knockdown signiﬁcantly decreases
K18 as well as K8 protein levels (Fig. 1E). Knockdown of Akt1 or
Akt2 individually in KLE cells was not sufﬁcient to decreased
vimentin protein levels (Fig. 1D). Altogether, these results reveal
that Akt regulates IFs protein levels in carcinoma cells, in an iso-
form-speciﬁc manner.
To determine whether the increase in IF proteins following Akt
over-expression requires new protein, the effect of cycloheximide,
a protein synthesis inhibitor, on Akt2-induced IFs expression was
studied in HeLa cells. The induction of IFs proteins by Akt2 was re-
duced following cycloheximide treatment (Fig. 2), suggesting that
new protein synthesis is required for the Akt2-induced IFs up-reg-
ulation. This suggests that Akt2 could modulates the stability of IFs
mRNA and leads to the increased IFs expression.
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Fig. 1. Intermediate ﬁlaments are differentially regulated by Akt1 and Akt2
isoforms in epithelial carcinoma cells. Protein levels of Akt1 or Akt2, pAkt, pGSK3,
K8/18 and vimentin were analyzed by Western blot in HeLa and HepG2 cells
transfected with control (empty) vector or with CA-Akt1 vector (A) or CA-Akt2
vector (B). mRNA levels of K8, K18 and vimentin were analyzed by quantitative
real-time RT-PCR in HeLa and HepG2 cells transfected with empty vector or with
CA-Akt1 vector (C) or CA-Akt2 vector (D). Protein levels of Akt1, Akt2, pAkt, K8/18
and vimentin were analyzed by Western blot in KLE cells transfected with control
(scrambled) shRNA or with Akt1 shRNA (E) or Akt2 shRNA (F). GAPDH or b-actin
was used as a loading control. H indicates a P-value of <0.05.
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Fig. 2. Akt2-induced intermediate ﬁlaments up-regulation requires new protein
synthesis. HeLa cells were transfected with control (empty) vector or CA-Akt2
vector and treated with cycloheximide (CHX) (20 lg/mL) or vehicle for 24 h. Protein
levels of Akt2, K8, K18 and vimentin were analyzed by Western blot. GAPDH was
used as a loading control.
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in epithelial carcinoma cells
Epiﬂuorescence microscopy using triple staining for pAkt, kera-
tins/vimentin and nuclei shows that transfection of CA-Akt2 in-
duces modiﬁcations of keratins and vimentin networks. In CA-
Akt2-transfected HeLa cells, pAkt shows a diffuse cytoplasmicstaining with a prominent localization at the cell membrane
(Fig. 3). In these cells, keratins and vimentin form a dense juxtanu-
clear cluster with little ﬁbrillar extension which is not observed in
non-transfected cells. These results indicate that IFs network orga-
nization is modulated by Akt2 activation. Akt is known to remodel
cytoskeleton by its interaction with actin in a cell migration con-
text [30]. We performed a rhodamin–phalloidin staining to deter-
mine if Akt2-induced IFs reorganization could induce actin
network remodelling. We observed that over-expression of Akt2
in HeLa cells induced actin cytoskeleton cortical remodelling,
which is characterized by a denser actin network at the cell periph-
ery. Taken together these results reveal that Akt2 regulates IFs and
actin networks organization in carcinoma cells.
3.3. IFs are up-regulated by TGF-b1 and insulin in PI3K-dependent
manner in epithelial carcinoma cells
To examine the regulation of IFs protein expression under a
more physiological condition, we treated p-Akt-positive KLE cells
with TGF-b1 or insulin, which are known to induce Akt activation
[31,32]. Exposure of the cells to TGF-b1 (Fig. 4A) or insulin (Fig. 4B)
increased the levels of Akt phosphorylation but did not modulate
the levels of K8/18. However, vimentin protein level is signiﬁcantly
up-regulated (Fig. 4A). Treatment with PI3K inhibitor LY294002
blocked the TGF-b1-induced up-regulation of vimentin. These ﬁnd-
ings show that activation of PI3K/Akt pathway following treatment
with physiological concentration of TGF-b1 is associated with
upregulation of vimentin, in agreement with our ﬁndings that
over-expression of constitutively active Akt proteins (Akt2 in this
case) increases vimentin protein levels (Fig. 1B).
4. Discussion
IFs protein expression pattern is commonly used as diagnostic
marker in tumor pathology [2]. In fact, epithelial tumors maintain
the keratin expression patterns of their respective cell type of ori-
gin and co-expression of vimentin is considered to be a marker of
de-differentiation (epithelial to mesenchymal transition) and inva-
siveness. In recent years, different studies have shown that IFs
should not be considered only as markers proteins but also as reg-
ulators of differentiation and that they might play an active role in
malignant transformation.
In this work, we investigated whether Akt isoforms could regu-
lates IFs expression in epithelial carcinoma cells. Our results show
that Akt1 up-regulates both K8 and K18 protein levels, whereas
Akt2 increases K18 and vimentin expression, while K8 expression
Fig. 3. Intermediate ﬁlaments cytoskeletal network is reorganized by Akt2 isoform in HeLa cells. HeLa cells were transfected with CA-Akt2 vector and triple
immunoﬂuorescence staining of Akt2 (green), keratins/vimentin/actin (red) and nuclei (blue) was performed.
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Fig. 4. TGF-b1- and insulin-stimulated Akt modulates intermediate ﬁlaments
expression via PI3K. KLE cells were treated for 24 h with TGF-b1 (10 nM) (A) or
insulin (200 nM) (B) in presence or not of PI3K inhibitor pre-treatment (LY294002
30 lM for 1 h). Protein levels of pAkt, K8, K18 and vimentin were analyzed by
Western blot. GAPDH was used as a loading control. H indicates a P-value of <0.05.
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lation mediated by Akt is isoform-speciﬁc. Although our results
show that the increase in IF proteins does not result from increased
transcription, it required new protein synthesis. Indeed, cyclohex-
imide treatment inhibits Akt2-induced IFs up-regulation. We sug-
gest that Akt could modulates mRNA stability and leads to the up-
regulation of IFs proteins. Some studies have already shown that
keratins protein synthesis could be regulated at a posttranscrip-
tional level, through a stabilization of mRNA transcripts [33–35].
It has been proposed that some physiological block in translation
prevents proteins synthesis until required during speciﬁc cell
states and we can extrapolate this hypothesis to our model in that
Akt activation could reverse the blocking of IFs translation in epi-
thelial carcinoma cells [36–38].
As obligate heteropolymers, K8/18 are known to be associated
and expressed in 1:1 ratio [1]. However, imbalance in K8/18 ratio
has been shown to occur in different pathological conditions. For
instance, K8 over-expression is associated with IFs aggregation
and Mallory–Denk body formation in mice hepatocytes [39]. In
vitro K18 over-expression has also been shown to induce IFs
aggregation [40]. However, the functional signiﬁcance of modiﬁ-
cations in K8/18 ratio in cells is not known. Our results show that
Akt2 induces an increase of K18 protein level, while K8 were not
signiﬁcantly modulated. The imbalance of K8/18 expression in
988 A.-M. Fortier et al. / FEBS Letters 584 (2010) 984–988Akt2-transfected cells could be related to vimentin, which are
also up-regulated by Akt2 in HeLa cells. It was already shown that
K18 could possibly interact with vimentin to form mixed ﬁla-
ments [41]. Another attractive explanation is that K18 could be
unpolymerized either in insoluble small aggregates [40] or in ﬁl-
amentous soluble pool, which could be undegraded due to their
association with other proteins such as trichoplein and desmopla-
kin [42]. All these possibilities need further investigation to be
elucidated.
In conclusion, these results represent the ﬁrst indication that
Akt could regulate IF protein levels in epithelial cancer cells. The
physiological signiﬁcance of differentially IFs up-regulation by
Akt1 and Akt2 isoforms is not elucidated yet but this work suggest
that IFs proteins are directly involved in PI3K/Akt signaling
pathway.
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